Roivant Sciences (NASDAQ:ROIV) Price Target Raised to $34.00

Roivant Sciences (NASDAQ:ROIV) had its target price boosted by HC Wainwright from $33.00 to $34.00 in a research report report published on Wednesday morning, MarketBeat Ratings reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Roivant Sciences’ Q3 2027 earnings at $0.32 EPS, Q4 2027 earnings at ($0.47) EPS and FY2027 earnings at ($1.03) EPS.

Several other equities research analysts have also issued reports on the company. Leerink Partners raised their target price on Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. TD Cowen restated a “buy” rating on shares of Roivant Sciences in a report on Saturday, February 7th. Guggenheim lifted their price objective on shares of Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. The Goldman Sachs Group boosted their target price on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Finally, Citigroup increased their target price on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, February 10th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $28.81.

Roivant Sciences Stock Down 3.2%

ROIV stock opened at $28.78 on Wednesday. The firm has a market cap of $20.60 billion, a PE ratio of -24.60 and a beta of 1.17. The business has a 50 day moving average of $24.56 and a 200-day moving average of $20.03. Roivant Sciences has a 12-month low of $8.73 and a 12-month high of $30.03.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, insider Mayukh Sukhatme sold 339,441 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $26.47, for a total transaction of $8,985,003.27. Following the completion of the transaction, the insider owned 19,148,664 shares in the company, valued at $506,865,136.08. This trade represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $26.49, for a total transaction of $5,298,000.00. Following the completion of the transaction, the chief executive officer owned 1,654,597 shares of the company’s stock, valued at $43,830,274.53. The trade was a 10.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 13,318,014 shares of company stock worth $315,727,023. Insiders own 10.80% of the company’s stock.

Institutional Trading of Roivant Sciences

A number of institutional investors have recently modified their holdings of ROIV. Pacer Advisors Inc. grew its stake in Roivant Sciences by 24.0% in the 4th quarter. Pacer Advisors Inc. now owns 70,259 shares of the company’s stock valued at $1,525,000 after buying an additional 13,609 shares in the last quarter. Dorsey Wright & Associates purchased a new stake in shares of Roivant Sciences during the fourth quarter worth $8,162,000. Invesco Ltd. boosted its holdings in shares of Roivant Sciences by 28.9% in the fourth quarter. Invesco Ltd. now owns 2,281,487 shares of the company’s stock worth $49,508,000 after acquiring an additional 512,129 shares during the period. Mercer Global Advisors Inc. ADV bought a new position in shares of Roivant Sciences in the fourth quarter worth $227,000. Finally, Empowered Funds LLC purchased a new position in shares of Roivant Sciences in the fourth quarter valued at $396,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.